BioSpace News Archive

Drug Development

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

Abbisko Therapeutics Co., Ltd. announced that the updated results of Phase Ib study of its CSF-1R inhibitor Pimicotinib in treating patients with advanced tenosynovial giant cell tumor, will be released at the 2023 American Society of Clinical Oncology annual meeting to be held in Chicago, USA from June 2 to June 6, 2023.

May 28, 2023
·
4 min read
Drug Development

Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

Harbour BioMed announced the results of phase Ib clinical trial of porustobart, in combination of toripalimab in patients with hepatocellular carcinoma were released at the American Society of Clinical Oncology Annual Meeting 2023.

May 28, 2023
·
4 min read